RGEN - Repligen Appoints Maggie A. Pax to Board of Directors | Benzinga
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company's multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer.
Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, "We're very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in the life sciences industry. I see Maggie as a strong fit with the Repligen leadership team; she brings an exceptional track record of guiding strategic change, developing go-to-market plans, creating business partnerships and driving product innovation programs."
Tony J. Hunt, Chief Executive Officer for Repligen said, "Maggie understands first-hand the drivers of growth for our industry and has touched many of ...